Hemophagocytic lymphohistiocytosis is a life-threatening syndrome, characterized by severe hyperinflammation and immunopathological manifestations in several tissues. These features result from organ infiltration by over-activated CD8 T-cells and macrophages, which produce high levels of pro-inflammatory cytokines, such as IFN-γ, TNF-α, IL6 and IL18. Recently, several JAK1/2 inhibitors, such as ruxolitinib, have been developed as immunosuppressive agents. They have proven beneficial effects in the treatment of myeloproliferative disorders and inflammatory conditions. In order to determine whether pharmacological inhibition of the JAK1/2, not only prevents the onset of HLH immunopathology, but is effective against existing HLH, cytotoxicity-impaired Prf1-/- and Rab27a-/- mice with full-blown HLH syndrome were treated with a clinically relevant dose of ruxolitinib. In vivo, ruxolitinib treatment suppressed STAT1 activation and led to recovery from HLH manifestations in both murine models. In the Prf1-/- mice, these beneficial effects were evidenced by a greater survival rate, and in both murine models, by the correction of blood cytopaenia and a rapid decrease in serum IL6 and TNF-αlevels. During ruxolitinib treatment, liver tissue damage receded, concomitantly with a decrease in the number of infiltrating inflammatory macrophages and an increase in the number of alternatively activated macrophages. In Rab27a-/- mice, central nervous system involvement was significantly reduced by ruxolitinib therapy. Our findings demonstrate that clinically relevant doses of the JAK1/2 inhibitor ruxolitinib, suppresses the harmful consequences of macrophage over-activation characterizing HLH in two murine models. The results could be readily translated into the clinic for the treatment of primary and perhaps even secondary forms of HLH.